William D. Gwynne

Dr. William D. Gwynne

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2021 in Molecules
Verified
Journal Article
Open access
PDF file
WGWilliam D. Gwynne
William D. Gwynne
MSMirza S. Shakeel
Mirza S. Shakeel
AGAdele Girgis-Gabardo
Adele Girgis-Gabardo
JHJohn Hassell
John Hassell
Breast tumors were the first tumors of epithelial origin shown to follow the cancer stem cell model. The model proposes that cancer stem cells are uniquely endowed with tumorigenic capacity and that their aberrant differentiation yields non-tumorigenic progeny, which constitute the bulk of the tumor cell population. Breast cancer stem cells resist therapies and seed metastases; thus, they account for breast cancer recurrence. Hence, targeting these cells is essential to achieve durable breast cancer remissions. We identified compounds including selective antagonists of multiple serotonergic system pathway components required for serotonin biosynthesis, transport, activity via multiple 5-HT receptors (5-HTRs), and catabolism that reduce the viability of breast cancer stem cells of both mouse and human origin using multiple orthologous assays. The molecular targets of the selective antagonists are expressed in breast tumors and breast cancer cell lines, which also produce serotonin, implying that it plays a required functional role in these cells. The selective antagonists act synergistically with chemotherapy to shrink mouse mammary tumors and human breast tumor xenografts primarily by inducing programmed tumor cell death. We hypothesize those serotonergic proteins of diverse activity function by common signaling pathways to maintain cancer stem cell viability. Here, we summarize our recent findings and the relevant literature regarding the role of serotonin in breast cancer.

10 December 2021 in Science Advances
Verified
Journal Article
Open access
DBDavid Bakhshinyan
David Bakhshinyan
AAAshley A. Adile
Ashley A. Adile
JLJeff Liu
Jeff Liu
WGWilliam D. Gwynne
William D. Gwynne
YSYujin Suk
Yujin Suk
Sheila SinghSheila Singh
Sheila Singh
Gene expression profiling of medulloblastoma cells undergoing therapy identifies BPIFB4 as a novel target for recurrent disease.